You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

TOSYMRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tosymra, and what generic alternatives are available?

Tosymra is a drug marketed by Tonix Meds and is included in one NDA. There are eight patents protecting this drug.

This drug has ninety-one patent family members in twenty-nine countries.

The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tosymra

A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TOSYMRA?
  • What are the global sales for TOSYMRA?
  • What is Average Wholesale Price for TOSYMRA?
Summary for TOSYMRA
International Patents:91
US Patents:8
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 70
Patent Applications: 4,196
Drug Prices: Drug price information for TOSYMRA
What excipients (inactive ingredients) are in TOSYMRA?TOSYMRA excipients list
DailyMed Link:TOSYMRA at DailyMed
Drug patent expirations by year for TOSYMRA
Drug Prices for TOSYMRA

See drug prices for TOSYMRA

US Patents and Regulatory Information for TOSYMRA

TOSYMRA is protected by eight US patents.

Patents protecting TOSYMRA

Formulations comprising triptan compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Formulations comprising triptan compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Alkylglycoside compositions for drug administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions for drug administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Formulations comprising triptan compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Compositions for drug administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Formulations comprising triptan compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Formulations comprising triptan compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tonix Meds TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for TOSYMRA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Galpharm Healthcare Ltd. Sumatriptan Galpharm sumatriptan EMEA/H/C/002140
Refused yes no no 2012-02-09
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for TOSYMRA

See the table below for patents covering TOSYMRA around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3082817 COMPOSITIONS POUR ADMINISTRATION DE MÉDICAMENTS (COMPOSITIONS FOR DRUG ADMINISTRATION) ⤷  Sign Up
Germany 112019000683 ⤷  Sign Up
Spain 2553862 ⤷  Sign Up
South Korea 101719008 ⤷  Sign Up
Canada 2814927 COMPOSITIONS POUR L'ADMINISTRATION DE MEDICAMENTS (COMPOSITIONS FOR DRUG ADMINISTRATION) ⤷  Sign Up
China 116549389 鼻内肾上腺素制剂及治疗疾病的方法 (Intranasal epinephrine formulations and methods of treating diseases) ⤷  Sign Up
Hong Kong 1164059 用於給藥的組合物 (COMPOSITIONS FOR DRUG ADMINISTRATION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.